Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Guangdong Biolight Meditech Co., Ltd. (300246.SZ)

7.18
+0.21
+(3.01%)
At close: April 30 at 3:04:43 PM GMT+8
Loading Chart for 300246.SZ
  • Previous Close 6.97
  • Open 6.66
  • Bid 7.21 x --
  • Ask 7.22 x --
  • Day's Range 6.93 - 7.32
  • 52 Week Range 5.43 - 9.15
  • Volume 9,907,602
  • Avg. Volume 9,991,392
  • Market Cap (intraday) 1.9B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.23
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 25, 2023
  • 1y Target Est --

Guangdong Biolight Meditech Co., Ltd. engages in the research and development, marketing, sale, and service of medical devices, medical consumables, and healthcare solutions. The company offers patient monitors, ECG monitoring equipment, fetal monitors, hemodialysis products, medical products, monitors, and accessories. It operates in Asia, Africa, Europe, North America, and Latin America. The company was founded in 1993 and is headquartered in Zhuhai City, China.

www.blt.com.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300246.SZ

View More

Performance Overview: 300246.SZ

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300246.SZ
8.95%
SSE Composite Index (000001.SS)
2.17%

1-Year Return

300246.SZ
4.51%
SSE Composite Index (000001.SS)
5.61%

3-Year Return

300246.SZ
19.81%
SSE Composite Index (000001.SS)
7.61%

5-Year Return

300246.SZ
46.45%
SSE Composite Index (000001.SS)
14.65%

Compare To: 300246.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300246.SZ

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    1.90B

  • Enterprise Value

    1.87B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.81

  • Price/Book (mrq)

    1.54

  • Enterprise Value/Revenue

    1.79

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.82%

  • Return on Assets (ttm)

    -0.61%

  • Return on Equity (ttm)

    -4.24%

  • Revenue (ttm)

    1.04B

  • Net Income Avi to Common (ttm)

    -60.62M

  • Diluted EPS (ttm)

    -0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    630.26M

  • Total Debt/Equity (mrq)

    45.59%

  • Levered Free Cash Flow (ttm)

    114.06M

Research Analysis: 300246.SZ

View More

Company Insights: 300246.SZ

Research Reports: 300246.SZ

View More

People Also Watch